In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.
ACT: How can more of a focus on site needs and challenges enhance the patient experience?
Davidson: Yeah, similar to the phrase, “Happy wife, happy life.” If you have happy sites and sites that are engaged and get through the study startup process, that hopefully translates to their ability to enroll patients, and also not just enroll patients, but to reduce the compliance issues that they're going to have throughout the study. If you can focus on training, if you can focus on engaging with that site and study startup, in addition to the conduct part of the study, then hopefully that translates into better quality patient enrollment as well.
ACT: What recent advancements in study startup technology excite you the most?
Davidson: I've got a couple answers to this question. The first is probably not quite as flashy, and I wouldn't necessarily call it innovation, but I think it's something worth calling out, is single sign on and not just any single sign on, really taking a more site-centric approach to single sign on and actually meeting sites where they are with their own technology landscapes, allowing them to log into sponsor provision technology with the same credentials they log into every single day. That's not really all that innovative, but I think it's really crucial in being able to move the needle a really substantial amount.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.